# A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

> **NCT03085069** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 146 (actual)

## Conditions studied

- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Respiratory Tract Neoplasms Nec
- Lung Disease
- Respiratory Tract Disease
- Neoplasm, Bronchial
- Carcinoma, Bronchogenic

## Interventions

- **BIOLOGICAL:** SHR-1210

## Key facts

- **NCT ID:** NCT03085069
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-03
- **Primary completion:** 2020-08-20
- **Final completion:** 2023-08-20
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085069, "A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03085069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*